The Novel Function of Unsymmetrical Chiral CCN Pincer Nickel Complexes as Chemotherapeutic Agents Targeting Prostate Cancer Cells

Jing-Jing Qu, Lin-Lin Shi *, Yan-Bing Wang, Jing Yan, Tian Shao *, Xin-Qi Hao, Jia-Xiang Wang, Hong-Yu Zhang *, Jun-Fang Gong * and Bing Song *

College of Chemistry, School of Life Sciences, School of Basic Medical Science, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, No. 100 of Science Road, Zhengzhou 450001, China; qujing0621@163.com (J.-J.Q.); 13027781853@163.com (Y.-B.W.); tjnuyj@163.com (J.Y.); shao_tian@zzu.edu.cn (T.S.); xqhao@zzu.edu.cn (X.-Q.H.); wjiaxiang@zzu.edu.cn (J.-X.W.)

* Correspondence: slinlinzzu@163.com (L.-L.S.); hyzhang@zzu.edu.cn (H.-Y.Z.); gongjf@zzu.edu.cn (J.-F.G.); bingsong@zzu.edu.cn (B.S.)

Abstract: We report that the pincer nickel complexes display prostate cancer antitumor properties through inhibition of cell proliferation. Notably, they display better antitumor properties than cisplatin. Mechanistic studies reveal that these pincer nickel complexes trigger cell apoptosis, most likely due to cell cycle arrest. Interestingly, these complexes also inhibit androgen receptor (AR) and prostate-specific antigen (PSA) signaling, which are critical for prostate cancer survival and progression. Our study reveals a novel function of pincer nickel complexes as potential therapeutic drugs in prostate cancer.

Keywords: pincer complex; nickel; prostate cancer; androgen receptor; PSA

1. Introduction

Prostate cancer (PCa) is the first and most common form of cancer and the second leading cause of cancer-related death among men in the United States. One in five men is expected to be diagnosed with PCa during his lifetime [1]. It is also the most rapidly increasing cancer type among men in China [2]. Although the 5-year survival rate of localized PCa is nearly 100%, metastatic PCa remains a deadly disease. While most advanced types of PCa initially respond to androgen deprivation therapy (ADT) with tumor regression, a majority of them eventually progress to a resistant disease referred to as castration-resistant prostate cancer (CRPC). Recent use of new-generation androgens such as abiraterone and enzalutamide (Enz) further prolonged patient lives for several months to a year; nevertheless, resistance inevitably develops, ultimately leading to death [3–6]. Sipuleucel-T (Provenge) is the only FDA-approved immunotherapy vaccine made for prostate cancer patients [7]. Balancing cost effectiveness, chemotherapy is still the first treatment used for advanced prostate cancer, although side effects are common. Thus, there is an urgent need to develop novel chemotherapeutic drugs against PCa.

Metal-based complexes have been used in cancer therapy since the discovery of the platinum compound (cisplatin) in the 1960s. They have the advantage of potential chemotherapeutic and cost-effective properties. Cisplatin has been the most successful anticancer drug used to treat many types of cancer; however, it has an uncertain effect on PCa and moderately decreases prostate-specific antigen (PSA), mainly due to its cellular toxicity and acquired resistance [8–12]. For these reasons, anticancer compounds with other kinds of metal are being investigated. Therefore, ruthenium, gold, and iron anticancer complexes have been tested to avoid severe side effects. The working mechanism and toxicity profile of drugs incorporating other metals than platinum may be distinct from platinum drugs and, thus, offer advantages over existing therapeutic regimens [13–16].
Nickel is abundant in our environment and ubiquitous in a variety of foods. Although in a trace amount, it is essential in physiological processes in our body [17]. Nickel complexes could be applied as valuable alternatives to anticancer platinum agents. Indeed, nickel-incorporated complexes have shown anticancer properties in prostate, breast, lung, and colon cancer cells [18–20].

In a previous study, we synthesized and characterized a series of pincer nickel complexes [21]. In the present study, we tested the cell viability of prostate cancer cells after treatment of these organometallic pincer compounds that have been previously designed, synthesized, and characterized by our group. Four pincer nickel complexes showed significant inhibitory effects in prostate cancer cells, triggering cell cycle arrest and higher levels of apoptosis with low IC50. This inhibitory effect occurs in both androgen-sensitive and androgen-insensitive prostate cancer cells. The mechanism of reduced cell growth is due to the repression of AR/PSA survival signaling, which is vital in promoting prostate cancer.

2. Results
2.1. Chemical Synthesis

We previously synthesized a series of pincer metal compounds in order to screen and test the biological function of these compounds. The synthesis of unsymmetrical chiral ligand precursors and the pincer nickel metal compounds is shown in Scheme 1 [21].

Scheme 1. Preparation of unsymmetrical chiral NHC imidazoline ligand precursors and CCN pincer Ni complexes.

2.2. Cytotoxic Studies

Since these compounds were stable under normal physiological conditions, we assessed the cytotoxic effect of these compounds on two representative prostate cancer cells—LNCaP (androgen-sensitive) and PC-3 (androgen-insensitive) cells. WST-1 test was performed with concentrations of compounds at 0, 1, 2.5, 5, and 10 μM on all cell lines. Four compounds showed significant inhibition of growth in LNCaP cells (Figure 1). It is interesting to note that these four compounds also showed significant inhibition of cell growth in PC-3 cells, which are considered androgen-insensitive and cisplatin-resistant cell lines (Figure 2). In summary, these results indicate that these pincer nickel complexes have growth inhibitory activity toward prostate cancer cells. Using logistic regression, IC50 concentrations were determined at 48 h of treatment in LNCaP cells (Table 1). Thus, we chose 5 μM for further mechanism study.
were treated for 48 h with chemicals at different concentrations and analyzed via WST-1 cell growth assay: (a) chemical 4a; (b) chemical 4b; (c) chemical 4c; (d) chemical 4d.

Figure 2. Synthesized chemicals inhibit PC-3 cell survival in a dose-dependent manner. PC-3 cells were treated for 48 h with chemicals at different concentrations and analyzed via WST-1 cell growth assay: (a) chemical 4a; (b) chemical 4b; (c) chemical 4c; (d) chemical 4d.

Table 1. The IC$_{50}$ of values of nickel complex in LNCaP cells.

|   | IC$_{50}$ (μM) |
|---|--------------|
| Chemical 4a | 5.23 μM |
| Chemical 4b | 4.68 μM |
| Chemical 4c | 5.33 μM |
| Chemical 4d | 4.33 μM |
2.3. Cell Cycle Analysis

Regulation of the cell cycle is a homeostatic mechanism that maintains proper cellular function. Many chemotherapeutic drugs have demonstrated their anticancer effects through disruption of the cell cycle. To reveal the impact of these compounds on the cell cycle, flow cytometric analysis was performed. LNCaP cells were treated with 5 µM of different compounds for 48 h. As shown in Figure 3, all four compounds increased the proportion of sub-G1 stage cells, which are considered to be apoptotic cells. This is consistent with our previous proliferation assay results. Interestingly, compounds 4a, 4b, and 4d induced S phase arrest, whereas compound 4c caused G2/M phase arrest. These results indicate that these pincer nickel compounds are able to induce cell cycle arrest, followed by cell apoptosis.

![Figure 3. Nickel complexes inhibit cell cycle progression in LNCaP cells. LNCaP cells were treated with or without 5 µM of chemicals and harvested for FACS analysis.](image)

We performed Annexin V-APC/7-AAD staining analysis to improve our cell death analysis. As shown in Figure 4A, the early and late apoptotic rates were markedly increased in cells treated with compounds 4a and 4c, compared with the control. In addition, there was no significant difference in the number of early apoptotic cells among the groups treated with compounds 4a and 4c. Notably, there were more late apoptotic cells in the group treated with 4a (Figure 4B). These results are consistent with our previous cell cycle analysis.
Figure 4. Cell apoptosis analysis using Annexin V-APC/7-AAD staining and flow cytometry in LNCaP cells treated with complexes: (A) representative image of cell apoptosis analysis with flow cytometry. Early-stage apoptotic cells are presented in the lower right quadrants (Annexin V-APC positive and 7AAD negative), and late-stage apoptotic cells are presented in the upper right quadrants (Annexin V-APC and 7AAD positive); (B) quantitative analysis of early, late-stage, and total apoptotic cell percentage in LNCaP cells treated with compounds. All experiments were repeated three times for data analysis. (* p < 0.05, *** p < 0.001, ● represents the results obtained from three independent experiments).

2.4. Cell Death Analysis

Cleaved PARP is one of the most used diagnostic markers for the detection of apoptosis. To investigate the effect of the compounds in inducing the intrinsic apoptotic pathway, we examined the levels of cleaved PARP protein (Figure 5). LNCaP cells were treated with 5 µM of compounds 4a and 4c for 48 h and subjected to Western blot analysis. As expected, the expression of apoptotic-protein-cleaved PARP was high in groups treated with compounds 4a and 4c, compared with that in the control group. The activation of this protein led to cell apoptosis, which is consistent with our proliferation and FACS analysis.

2.5. AR and PSA Expression Analysis

It is well recognized that AR signaling plays a central role in the development and progression of PCA. Prostate-specific antigen (PSA) expression is the clinically validated downstream indicator of androgen receptor activity and an important marker for prostate cancer progression in patients. Thus, we treated LNCaP cells with chemicals 4a or 4c and examined expressions of AR and PSA. Figure 4 shows that AR was highly expressed in LNCaP cells. However, in the presence of chemical 4a or 4c, the expression of AR protein significantly decreased. The PSA expression also decreased, which is consistent with our observation of cell proliferation.
Figure 5. Nickel complexes induce LNCaP cell death (A) through inhibition of cleaved PARP (B), AR (C), and PSA (D) signaling.

3. Discussion

One of the main characteristics of PCa is hormonal reactivity. Androgen receptor activation is necessary for the normal growth of the prostate. Aberrant AR signaling is also one of the major reasons for prostate cancer occurrence and progression. Early-stage PCa initially responds to androgen deprivation therapy (ADT) with tumor regression but eventually develops into metastatic castration-resistant prostate cancer (mCRPC) [22,23]. In this study, the pincer nickel complexes were screened for their antiproliferative activity against prostate cancer cells. Interestingly, they showed cytotoxic activity on both androgen-sensitive prostate cancer cells (LNCaP) and androgen-insensitive prostate cancer cells (PC-3). Further mechanistic studies suggest that these pincer nickel complexes kill prostate cancer cells via apoptosis. This is, in part, due to cell cycle arrest and repressed expressions of AR signaling. The downregulation of PSA observed in LNCaP cells treated with complexes is consistent with their ability to downregulate AR. Since the PSA gene is one of the major AR regulated genes, it is speculated that the reduction in AR leads to a decline in PSA.

4. Materials and Methods

4.1. Chemical Synthesis

Cisplatin (Beyotime Biotechnology, Shanghai, China, S1552) was prepared and used as suggested by the manufacturers. Chemicals were synthesized as previously described [21]. In a 25 mL two-necked Schlenk tube, compound 3 (0.44 mmol), NaOAc (0.36 g, 4.40 mmol), and NiCl₂ (0.11 g, 0.88 mmol) were added in dry DMAc (10 mL). The mixture was refluxed under an Ar atmosphere for 24 h. After the mixture was cooled and concentrated in vacuo, the residue was purified by passing through a short column containing a layer of Celite and a layer of silica with dichloromethane as eluent. The desired products of 4 (including 4a, 4b, 4c, and 4d) were purified once again by preparative TLC on silica gel plates with CH₂Cl₂/EtOAc 1/1 as eluent.
4.2. Cell Culture and Reagents

PCa cell lines LNCaP and PC-3 were obtained from Stem Cell Bank, Chinese Academy of Sciences. All cell lines were authenticated and tested free of mycoplasma. LNCaP and PC-3 cells were cultured in RPMI 1640 with 10% fetal bovine serum and 1% penicillin–streptomycin. The cells were maintained at 37 °C in a humidified incubator with 5% carbon dioxide.

4.3. Cell Proliferation Assay

The proliferation assay was performed using WST-1 (Beyotime Biotechnology, Shanghai, China, C0036), as described by the manufacturer. In brief, 3000 LNCaP or PC-3 cells/well were seeded in 96-well plates. Cells were either treated with vehicle (DMSO) or different concentrations of compounds, 10 µL of WST-1 was added to the cultures and incubated for 2 h when harvesting, and the absorbance was measured at 450 nm using a spectrophotometer.

4.4. Cell Cycle and Apoptosis Analysis

Cell cycle and apoptosis analysis were performed as described by the manufacturer (Beyotime Biotechnology, Shanghai, China, C1052). Cells were harvested via trypsinization, fixed in 75% ethanol, stained with propidium iodide solution at a final concentration of 50 µg/mL, and subjected to fluorescence-activated cell sorting (FACS) analysis.

4.5. Antibodies and Western Blots

Antibodies used in the Western blots were GAPDH (Abcam, Shanghai from China, ab9484), cleaved PARP (Cell Signaling, Shanghai, China. 5625S), androgen receptor (Cell Signaling, Shanghai, China. 5153S), and PSA (Cell Signaling, Shanghai from China, 2475S); all antibodies were diluted as suggested by the manufacturers. Western blot analyses were performed using standard protocols. In brief, cell lysates were dissolved in 1XNP40 sample buffer, sonicated, and quantified by Bradford Protein Assay Kit (Beyotime Biotechnology, Shanghai, China, P0006) and then boiled with 1XSDS loading dye for 10 min at 95 °C, separated on a 4–20% Precast PAGE gel for Tris-Gly system (Beyotime Biotechnology, Shanghai, China, P0468S), and transferred to a PVDF membrane. The membranes were blocked with 5% milk in PBST for 1h at RT, incubated in primary antibody diluted in primary antibody dilution buffer (Beyotime Biotechnology, Shanghai, China, P0023A) overnight at 4 °C, washed 3 × with PBST, and incubated for 1 h in a secondary antibody (Sangon Biotech, Shanghai, China, 1:5000). Membranes were washed 3 × with PBST and subjected to development.

4.6. Statistical Analysis

Two-tailed paired t-tests were used to assess the statistical significance of cell functional assays.

5. Conclusions

Although various ways have been investigated to treat prostate cancer, chemical therapy is still the first line of treatment for prostate cancer [23]. In the present study, we showed that pincer nickel compounds have antiproliferative activity for prostate cancer cells. Androgen insensitivity is one of the major reasons for prostate cancer therapy failure. These types of nickel complexes have inhibitory activity toward both androgen-sensitive and androgen-insensitive cell lines, indicating that pincer nickel complexes can be used in patients with androgen insensitivity.

Nickel has been reported to induce mitochondrial apoptosis and caspase-dependent apoptosis [17]. Whether it is the compound or the nickel ion that plays a major role in the results generated in our study still needs further investigation. We also observed that all four complexes induced cell cycle arrest and cell death, but complex 13 exhibited significant mitotic arrest other than S-phase arrest. This may indicate a different mechanism.
Taken together, we showed that pincer nickel complexes exert antiproliferative activity via induction of cell cycle arrest. These complexes can also downregulate the protein expression of AR and PSA in LNCaP cells. Our research suggests a new category of complexes with anticancer properties.

**Author Contributions:** J.-F.G., J.-X.W., H.-Y.Z., L.-L.S. and B.S. conceptualized the study. J.-J.Q., Y.-B.W., J.Y., T.S. and B.S. designed and conducted most of the experiments. The manuscript was written by J.-J.Q., X.-Q.H., L.-L.S. and B.S., with assistance from all authors. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported, in part, by the National Natural Science Foundation of China (Grant No. 31801092, 22101267), Henan Provincial Natural Science Foundation of Excellent Youth Fund (Grant No. 212300410069), the China Postdoctoral Science Foundation (Grant No. 2018M642773), Foundation of Henan Educational Committee (Grant No. 18A180007).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** The authors are thankful to colleagues at Zhengzhou University for their help in conducting this study.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. *CA Cancer J. Clin.* **2020**, *70*, 7–30. [CrossRef] [PubMed]
2. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2016. *CA Cancer J. Clin.* **2016**, *66*, 6–7–30. [CrossRef] [PubMed]
3. Davis, I.D.; Martin, A.J.; Stockler, M.R.; Begbie, S.; Chi, K.N.; Chowdhury, S.; Coskinas, X.; Frydenberg, M.; Hague, W.E.; Horvath, L.G.; et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. *N. Engl. J. Med.* **2019**, *381*, 121–131. [CrossRef] [PubMed]
4. Chi, K.N.; Agarwal, N.; Bjartell, A.; Chung, B.H.; Pereira de Santana Gomes, A.J.; Given, R.; Soto, A.J.; Merseburger, A.S.; Ozgüroğlu, M.; Uemura, H.; et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. *N. Engl. J. Med.* **2019**, *381*, 13–24. [CrossRef] [PubMed]
5. de Bono, J.S.; Logothetis, C.J.; Molina, A.; Fizazi, K.; North, S.; Chu, L.; Chu, L.; Chi, K.N.; Jones, R.J.; Goodman, O.B.; et al. Abiraterone and Increased Survival in Metastatic Prostate Cancer REPLY. *N. Engl. J. Med.* **2011**, *365*, 765–768.
6. Scher, H.I.; Fizazi, K.; Saad, F.; Taplin, M.E.; Sternberg, C.N.; Miller, K.; De Wit, R.; Mulders, P.; Chi, K.N.; Shore, N.D.; et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. *N. Engl. J. Med.* **2012**, *367*, 1187–1197. [CrossRef]
7. Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Persson, D.E.; Redlund, C.H.; Ferrari, A.C.; Dreicer, R; Sims, R.B.; et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N. Engl. J. Med.* **2010**, *363*, 411–422. [CrossRef]
8. Chiang, K.-C.; Tsui, K.-H.; Chung, L.-C.; Yeh, C.-N.; Feng, T.-H.; Chen, W.-T.; Chang, P.-L.; Chiang, H.-Y.; Huang, H.-H. Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways. *Sci. Rep.* **2014**, *4*, 5511. [CrossRef]
9. Yagoda, A.; Watson, R.C.; Natale, R.B.; Barzelli, W.; Sogani, P.; Grabstald, H.; Whitmore, W.F. A critical analysis of response criteria in patients with prostatic cancer treated with cis-diaminedichloride platinum II. *Cancer* **1979**, *44*, 1553–1562. [CrossRef]
10. Qazi, R.; Khandekar, J. Phase II study of cisplatin for metastatic prostate carcinoma: An Eastern Cooperative Oncology Group study. *Am. J. Clin. Oncol.* **1993**, *6*, 203–205. [CrossRef]
11. Merrin, C.E. Treatment of genitourinary tumours with cis-dichlorodiammineplatinum(II) in patients with prostatic cancer treated with cis-diaminedichloride platinum II. *Cancer* **1979**, *44*, 1553–1562. [CrossRef]
12. Moore, M.R.; Troner, M.B.; de Simone, P.; Birch, R.; Irwin, L. Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: A Southeastern Cancer Study Group Trial. *Cancer Treat. Rep.* **1986**, *70*, 541–542. [PubMed]
13. de Sousa, I.H.; Campos, V.N.S.; Vale, A.A.M.; Maciel-Silva, V.L.; Leite, C.M.; Lopes, A.J.O.; Mourão, P.S.; Lima, F.D.C.A.; Batista, A.A.; Santos, A.P.S.D.A.D.; et al. Ruthenium (II) complexes with N, O-chelating proline and threonine ligands cause selective cytotoxicity by the induction of genomic instability, cell cycle arrest and apoptosis in breast and prostate tumor cells. *Toxicol. In Vitro* **2020**, *62*, 104679. [CrossRef] [PubMed]
14. de Grandis, R.A.; da Silva Dos Santos, P.W.; de Oliveira, K.M.; Machado, A.R.T.; Aissa, A.F.; Batista, A.A.; Antunes, L.M.G.; Pavan, F.R. Novel lawsonite-containing ruthenium(II) complexes: Synthesis, characterization and anticancer activity on 2D and 3D spheroid models of prostate cancer cells. *Bioorg. Chem.* **2019**, *85*, 455–468. [CrossRef] [PubMed]
15. Mangadlao, J.D.; Wang, X.N.; McCleese, C.; Escamilla, M.; Ramamurthy, G.; Wang, Z.; Govande, M.; Basilion, J.P.; Burda, C. Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer. *ACS Nano* **2018**, *12*, 3714–3725. [CrossRef] [PubMed]

16. Bordini, J.; Morisi, F.; Elia, A.R.; Santambrogio, P.; Pagani, A.; Cucchiara, V.; Ghia, P.; Bellone, M.; Briganti, A.; Camaschella, C.; et al. Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models. *Clin. Cancer Res.* **2020**, *26*, 6387–6398. [CrossRef]

17. Genchi, G.; Carocci, A.; Lauria, G.; Sinicropi, M.S.; Catalano, A. Nickel: Human Health and Environmental Toxicology. *Int. J. Environ. Res. Public Health* **2020**, *17*, 679. [CrossRef]

18. Zhu, T.; Wang, Y.; Ding, W.; Xu, J.; Chen, R.; Xie, J.; Zhu, W.; Jia, L.; Ma, T. Anticancer activity and DNA-binding investigations of the Cu(II) and Ni(II) complexes with coumarin derivative. *Chem. Biol. Drug Des.* **2015**, *85*, 385–393. [CrossRef]

19. Feld, C.J.; Johnson, A.; Xiao, Z.Y.; Suntharalingam, K. Breast Cancer Stem Cell Potency of Nickel(II)-Polypyridyl Complexes Containing Non-steroidal Anti-inflammatory Drugs. *Chem. Eur. J.* **2020**, *26*, 14011–14017. [CrossRef]

20. Heng, M.P.; Sim, K.S.; Tan, K.W. Nickel and zinc complexes of testosterone N4-substituted thiosemicarbazone: Selective cytotoxicity towards human colorectal carcinoma cell line HCT 116 and their cell death mechanisms. *J. Inorg. Biochem.* **2020**, *208*, 111097. [CrossRef]

21. Yan, J.; Wang, Y.B.; Zhu, Z.H.; Li, Y.G.; Zhu, X.J.; Hao, X.Q.; Song, M.P. Synthesis, Characterization, and Catalytic Studies of Unsymmetrical Chiral NCC Pincer Pd(II) and Ni(II) Complexes Bearing (Imidazolinyl)aryl NHC Ligands. *Organometallics* **2018**, *37*, 2325–2334. [CrossRef]

22. Snow, O.; Lallous, N.; Singh, K.; Lack, N.; Rennie, P.; Cherkasov, A. Androgen receptor plasticity and its implications for prostate cancer therapy. *Cancer Treat. Rep.* **2019**, *81*, 101871. [CrossRef] [PubMed]

23. Komura, K.; Sweeney, C.J.; Inamoto, T.; Ibuki, N.; Azuma, H.; Kantoff, P.W. Current treatment strategies for advanced prostate cancer. *Int. J. Urol.* **2018**, *25*, 220–231. [CrossRef] [PubMed]